Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.

Study Overview

• Status: Recruiting
• Conditions: Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
• Intervention / Treatment: Procedure: Computed Tomography; Procedure: Biospecimen Collection; Procedure: Positron Emission Tomography; Procedure: Bone Marrow Biopsy; Drug: Tegavivint; Procedure: Bone Marrow Aspiration

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the safety and tolerability of tegavivint in patients with relapsed/refractory c-Myc overexpressing large B-cell lymphoma.

II. To determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of tegavivint.

SECONDARY OBJECTIVES:

I. To determine the preliminary efficacy of tegavivint in patients with relapsed/refractory c-Myc overexpressing large B-cell lymphoma.

II. To determine the pharmacokinetic parameters of tegavivint.

EXPLORATORY OBJECTIVES:

I. To correlate response to tegavivint with the presence of MYC, FBW7 and SKP2 mutations.

II. To correlate response to tegavivint with TBL1 and c-Myc expression assessed by standard IHC on archived tumor biopsy.

III. To determine the effects of tegavivint on immune cell subsets viability and function.

OUTLINE: This is a dose-escalation study of tegavivint.

Patients receive tegavivint intravenously (IV) on study. Patients also undergo computed tomography (CT) and/or positron emission tomography (PET) and undergo blood sample collection throughout the trial.

• Study Type: Interventional
• Enrollment (Estimated): 18
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: The Ohio State Comprehensive Cancer Center; Phone Number: 800-293-5066; Email: OSUCCCClinicaltrials@osumc.edu

Study Locations

• United States
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Recruiting
      • Ohio State University Comprehensive Cancer Center
      • Contact: Lapo Alinari, MD, PhD; Phone Number: 614-293-5594; Email: Lapo.Alinari@osumc.edu
      • Principal Investigator: Lapo Alinari, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

One of the following three conditions:

• Relapsed/refractory histologically confirmed germinal center B-cell-like (GCB) and non-GCB diffuse large B cell lymphoma (DLBCL) with the following features:

  • Increased expression of MYC (>= 40%) and BCL2 (>= 50%) by immunohistochemistry (IHC) or
  • Presence of isolated MYC translocation Or
• Relapsed/refractory histologically confirmed high-grade B-cell lymphoma (HGBCL) (double hit [DH] and triple hit [TH]) with translocations of MYC and BCL2 and/or BCL6 Or

• Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL

  • Presence of BCL2 translocation with increased expression of MYC (≥40%) with or without MYC translocation
• Patients must have had at least two prior systemic therapies
• Patients must be ineligible for or refused autologous or allogenic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy. Prior autologous stem cell transplant and/or CAR-T are allowed, if received >= 3 months prior to enrollment
• Age >= 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Patients must have radiographically measurable disease by standard positron emission tomography (PET) uptake with at least one site of measured disease by standardized uptake value (SUV)
• Absolute neutrophil count (ANC) ≥ 500/mcL
• Platelet count ≥ 25,000/mcL
• Total bilirubin =< 1.5 x the upper limit of the normal range (ULN)
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x institutional ULN
• Creatinine clearance >= 60 ml/min by Cockcroft-Gault (actual body weight will be used to estimate creatinine clearance)
• Patients must be willing and able to understand and give written informed consent and comply with all study related procedures
• Women of child-bearing potential (WOCBP) and men who are sexually active with WOCBP must agree to use one hormonal contraceptive (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation; and one effective method of contraception, including male condom, female condom, cervical cap, diaphragm or contraceptive sponge or abstain from sex for the duration of study participation and for 4 months following completion of tegavivint administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

Contraception includes:

• Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
• Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient
• Use of oral (estrogen and progesterone), injected or implanted combined hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
• Sexually active males must use a condom during intercourse while taking drug and for 4 months after stopping study treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential

Exclusion Criteria:

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to tegavivint or other agents used in study
• Known active central nervous system (CNS) lymphoma, history of CNS involvement allowed if in remission for >= 3 months
• Evidence of chronic active Hepatitis B, chronic active Hepatitis C infection
• Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy (e.g., strong CYP3A inhibitors and/or concomitant medications that are excluded) are ineligible because of the potential for pharmacokinetic interactions with tegavivint
• Known history of active TB (Bacillus Tuberculosis)
• Major surgery within 3 weeks prior to start of study treatment
• Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality or corrected QT interval (QTc) > 480 msec
• Uncontrolled concurrent illness including, but not limited to: ongoing or active infection (Viral, bacterial, fungal or other)
• Psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant and breastfeeding women are excluded from this study. The effects of tegavivint on the developing human fetus have the potential for teratogenic or abortifacient effects. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with tegavivint
• Patients with abnormal serum chemistry values other than the specific limits detailed above, that in the opinion of the investigator is considered to be clinically significant, should be discussed with the Study PI before being enrolled in the study

• Personal history of malignancy except:

  • Cervical intraepithelial neoplasia;
  • Skin basal cell carcinoma;
  • Treated localized prostate carcinoma with prostate specific antigen (PSA) <1 ng/mL or untreated indolent prostate cancer
  • Neoplasia treated with curative intent, in remission for at least three years and considered at low risk of relapse

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (Tegavivint); Patients receive tegavivint IV over 4 hours on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or PET and undergo blood sample collection throughout the trial. Patients may also undergo bone marrow biopsy and aspirate during screening and on the trial.

Procedure: Computed Tomography; Undergo CT; Other Names: CT; CAT; CAT Scan; Computed Axial Tomography; Computerized Axial Tomography; Computerized Tomography; CT Scan; tomography; Procedure: Biospecimen Collection; Undergo blood sample collection; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Procedure: Positron Emission Tomography; Undergo PET scan; Other Names: Medical Imaging, Positron Emission Tomography; PET; PET Scan; Positron Emission Tomography Scan; Positron-Emission Tomography; proton magnetic resonance spectroscopic imaging; PT; Procedure: Bone Marrow Biopsy; Undergo bone marrow biopsy and aspiration; Other Names: Biopsy; Bone marrow; Biopsy of bone marrow; Drug: Tegavivint; Given IV; Other Names: BC 2059; BC-2059; BC2059; Tegatrabetan; Procedure: Bone Marrow Aspiration; Undergo bone marrow biopsy and aspiration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (MTD) for tegavivint	Determination of the MTD of tegavivint using a 3+3 design.	At the end of Cycle 1 (each cycle is 28 days)
Incidence of dose-limiting toxicity	1) To be declared as dose-limiting toxicity, an adverse event must be related (definite, probable, or possible) to study treatment during the first cycle of therapy only (first 28 days). Any death at least possibly related to tegavivint will be a DLT. No DLTs observed thus far.	At the end of Cycle 1 (each cycle is 28 days)
Determination of the recommended phase II dose (RP2D) of tegavivint	2) This study uses a traditional "3+3" designs. We therefore anticipate a total sample size of 12 with the maximum expected sample size of 24. Primary endpoint not yet reached.	At the end of Cycle 1 (each cycle is 28 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate (ORR)	Will be estimated by molecular subtype and across subtypes with exact 80% and 90% confidence intervals.	After cycle 2 (each cycle is 28 days) or end of treatment
Complete response (CR) rate	Will be estimated by molecular subtype and across subtypes with exact 80% and 90% confidence intervals.	At the end of Cycle 2 (each cycle is 28 days)
Duration of response (DOR)	Will be summarized by the Kaplan-Meier method, and two-year estimates will be provided with 80% and 90% confidence intervals, for each subtype and for all patients.	Time from the date of first response until the first date of progression or death from any cause, assessed up to 2 years from study enrollment
Progression-free survival (PFS)	Will be summarized by the Kaplan-Meier method, and two-year estimates will be provided with 80% and 90% confidence intervals, for each subtype and for all patients.	Time from the date of first treatment until the first date of progression or death from any cause, assessed up to 2 years from study enrollment
Event-free survival (EFS)	Will be summarized by the Kaplan-Meier method, and two-year estimates will be provided with 80% and 90% confidence intervals, for each subtype and for all patients.	Time from the date of first treatment until the first date of progression, re-treatment of lymphoma after initial immune-therapy, or death from any cause, assessed up to 2 years from study enrollment
Overall survival (OS)	Will be summarized by the Kaplan-Meier method, and two-year estimates will be provided with 80% and 90% confidence intervals, for each subtype and for all patients.	Time from the date of first treatment until the date of death from any cause, assessed up to 2 years from study enrollment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic (PK) analysis AUC0-t	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using AUC0-t	Up to 14 weeks
Pharmacokinetic (PK) analysis AUC0-infinity	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using AUC0-infinity.	Up to 14 weeks
Pharmacokinetic (PK) analysis Tmax	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using Tmax	Up to 14 weeks
Pharmacokinetic (PK) analysis Cmax	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using Cmax.	Up to 14 weeks
Pharmacokinetic (PK) analysis t1/2	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using t1/2.	Up to 14 weeks
Pharmacokinetic (PK) analysis clearance	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using clearance.	Up to 14 weeks
Pharmacokinetic (PK) analysis volume of distribution	The reporting of pharmacokinetic parameters will be determined based on the final parameter analysis on the available data. Parameters will be assessed using volume of distribution.	Up to 14 weeks

Collaborators and Investigators

• Sponsor: Lapo Alinari
• Investigators: Principal Investigator: Lapo Alinari, MD, PhD, Ohio State University Comprehensive Cancer Center

Publications and helpful links

Helpful Links

• The Jamesline

Study record dates

Study Major Dates

• Study Start (Actual): March 6, 2023
• Primary Completion (Estimated): March 5, 2028
• Study Completion (Estimated): March 5, 2028

Study Registration Dates

• First Submitted: February 1, 2023
• First Submitted That Met QC Criteria: March 2, 2023
• First Posted (Actual): March 6, 2023

Study Record Updates

• Last Update Posted (Actual): February 27, 2026
• Last Update Submitted That Met QC Criteria: February 24, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Disease Attributes; Immune System Diseases; Neoplasms by Histologic Type; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Recurrence; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Investigative Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Surgical Procedures, Operative; Cytological Techniques; Cytodiagnosis; Diagnostic Techniques, Surgical; Chemistry Techniques, Analytical; Spectrum Analysis; Biopsy; Specimen Handling; Magnetic Resonance Spectroscopy
• Other Study ID Numbers: OSU-21359; NCI-2023-00200 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No